Celgene Corp
NASDAQ:CELG
$74.95
$0.81
(1.09%)
Quote as of 1:25 PM EST on 02/15/12
|
$74.95
$0.81
(1.09%)
|
|
| Today's Open | $74.36 |
|---|---|
| Previous Close | $74.15 |
| Daily Range | $73.83 - $76.09 |
| 52-Week Range | $51.41 - $76.09 |
| Market Cap | $33.27B |
| P/E Ratio | 19.56 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 3,181,554 |
| Average Daily Volume | 3,529,339 |
| Current FY EPS | $4.41 |
CELG Information
| Description |
|---|
| A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. |
| Sector |
| Healthcare |
| Industry |
| Biotechnology |
News & Commentary
Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF,
Blood Disease Drug Dacogen Gets Thumbs Down for Cancer Use
3 Biotechnology Stocks for Short-Term Traders
Has Amgen Become the Perfect Stock?
Which Big Biotech Is the Best Bet?
Celgene Meets on the Top Line, Misses Where It Counts
2 Biotech Acquisitions in 1 Day! Let's Throw a Party
Celgene Misses Narrowly in 4Q - Analyst Blog
UPDATE: Celgene To Buy Avila For Up To $925 Million; 4Q Net Up 96%
Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies
